September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Overview of Ocular GVHD as Area of Significant Unmet Medical Need
Author Affiliations & Notes
  • Reza Dana
    Mass. Eye & Ear Infirmary / Harvard Medical School, Boston, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Reza Dana, Cambium (C), Eleven Bio (I)
  • Footnotes
    Support  NIH EY020889
Investigative Ophthalmology & Visual Science September 2016, Vol.57, No Pagination Specified. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Reza Dana; Overview of Ocular GVHD as Area of Significant Unmet Medical Need. Invest. Ophthalmol. Vis. Sci. 201657(12):.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Presentation Description : A majority of long-term survivors of hematopoietic stem cell / bone marrow transplant recipients are at risk of developing graft-versus-host disease (GVHD). Chronic ocular GVHD is a common, though relatively late, complication seen in these patients and is typically characterized by severe inflammation of the ocular surface associated with various manifestations of dry eye disease- ranging from relatively mild surface epitheliopathy to a severe sicca syndrome presenting as filamentary keratitis, epithelial sloughing, and in some cases stromal thinning and bilateral corneal perforation. There is currently no specific “standard of care” for the management of the ocular manifestations of GVHD. This talk will provide an overview of the unmet medical needs in this severe ocular surface pathology and provide a brief summary of a rational approach to its management.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.